Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Franco Locatelli; G. Zugmaier; C. Rizzari; J. D. Morris; B. Gruhn; T. Klingebiel; R. Parasole; C. Linderkamp; C. Flotho; A. Petit; C. Micalizzi; Y. Zeng; R. Desai; W. N. Kormany; C. Eckert; A. Moricke; M. Sartor; O. Hrusak; C. Peters; V. Saha; L. Vinti; A. von Stackelberg

doi:10.1038/s41375-022-01770-3

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Franco Locatelli^*
, G. Zugmaier
, C. Rizzari
, J. D. Morris
, B. Gruhn
, T. Klingebiel
, R. Parasole
, C. Linderkamp
, C. Flotho
, A. Petit
, C. Micalizzi
, Y. Zeng
, R. Desai
, W. N. Kormany
, C. Eckert
, A. Moricke
, M. Sartor
, O. Hrusak
, C. Peters
, V. Saha

L. Vinti, A. von Stackelberg

^*Corresponding author

Amgen Incorporated
University of Milan - Bicocca
Universitaetsklinikum Jena
Goethe University Frankfurt
Azienda Ospedaliera Santobono Pausillipon
Hannover Medical School
University of Freiburg
Hôpital Armand Trousseau
Istituto Pediatrico di Ricovero e Cura a Carattere Scientifico G Gaslini
IQVIA Inc.
Charité – Universitätsmedizin Berlin
Westmead Hospital
Charles University
St. Anna Kinderspital
University of Manchester

Research output: Contribution to journal › Article

Abstract

NO ABSTRACT

Original language	English
Pages (from-to)	222-225
Number of pages	4
Journal	Leukemia
Volume	37
Issue number	1
DOIs	https://doi.org/10.1038/s41375-022-01770-3
Publication status	Published - 2023

All Science Journal Classification (ASJC) codes

Hematology
Oncology
Cancer Research

Keywords

BLINATUMOMAB

Access to Document

10.1038/s41375-022-01770-3

Cite this

Locatelli, F., Zugmaier, G., Rizzari, C., Morris, J. D., Gruhn, B., Klingebiel, T., Parasole, R., Linderkamp, C., Flotho, C., Petit, A., Micalizzi, C., Zeng, Y., Desai, R., Kormany, W. N., Eckert, C., Moricke, A., Sartor, M., Hrusak, O., Peters, C., ... von Stackelberg, A. (2023). Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. Leukemia, 37(1), 222-225. https://doi.org/10.1038/s41375-022-01770-3

@article{e76adb53af6f4813ae65bdaa97555d5a,

title = "Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL",

abstract = "NO ABSTRACT",

keywords = "BLINATUMOMAB, BLINATUMOMAB",

author = "Franco Locatelli and G. Zugmaier and C. Rizzari and Morris, \{J. D.\} and B. Gruhn and T. Klingebiel and R. Parasole and C. Linderkamp and C. Flotho and A. Petit and C. Micalizzi and Y. Zeng and R. Desai and Kormany, \{W. N.\} and C. Eckert and A. Moricke and M. Sartor and O. Hrusak and C. Peters and V. Saha and L. Vinti and \{von Stackelberg\}, A.",

year = "2023",

doi = "10.1038/s41375-022-01770-3",

language = "English",

volume = "37",

pages = "222--225",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "1",

}

Locatelli, F, Zugmaier, G, Rizzari, C, Morris, JD, Gruhn, B, Klingebiel, T, Parasole, R, Linderkamp, C, Flotho, C, Petit, A, Micalizzi, C, Zeng, Y, Desai, R, Kormany, WN, Eckert, C, Moricke, A, Sartor, M, Hrusak, O, Peters, C, Saha, V, Vinti, L & von Stackelberg, A 2023, 'Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL', Leukemia, vol. 37, no. 1, pp. 222-225. https://doi.org/10.1038/s41375-022-01770-3

TY - JOUR

T1 - Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

AU - Locatelli, Franco

AU - Zugmaier, G.

AU - Rizzari, C.

AU - Morris, J. D.

AU - Gruhn, B.

AU - Klingebiel, T.

AU - Parasole, R.

AU - Linderkamp, C.

AU - Flotho, C.

AU - Petit, A.

AU - Micalizzi, C.

AU - Zeng, Y.

AU - Desai, R.

AU - Kormany, W. N.

AU - Eckert, C.

AU - Moricke, A.

AU - Sartor, M.

AU - Hrusak, O.

AU - Peters, C.

AU - Saha, V.

AU - Vinti, L.

AU - von Stackelberg, A.

PY - 2023

Y1 - 2023

N2 - NO ABSTRACT

AB - NO ABSTRACT

KW - BLINATUMOMAB

UR - https://publicatt.unicatt.it/handle/10807/229144

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85143596062&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85143596062&origin=inward

U2 - 10.1038/s41375-022-01770-3

DO - 10.1038/s41375-022-01770-3

M3 - Article

SN - 0887-6924

VL - 37

SP - 222

EP - 225

JO - Leukemia

JF - Leukemia

IS - 1

ER -

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this